Carbapenems in the Treatment of Severe Community-Acquired Pneumonia in Hospitalized Elderly Patients: A Comparative Study Against Standard Therapy

References

• Rajagopalan S, Yoshikawa T. Antimicrobial therapy in the elderly. Antibiot Ther 2001; 1: 133–47.
   Google Scholar
• Maston BJ, Plouffe JF, File Jr TM, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997; 157: 1709–18.
   PubMedGoogle Scholar
• Palmer CS, Zhan C, Elixhauser A, et al. Economic assessment of the community-acquired pneumonia interven-tion trial employing levofloxacin. Clin Therapeut 2000; 22, 2: 250–64.
   PubMed Web of Science ®Google Scholar
• Garcia-Ord6tiez MA, Garcia-Jimênez JM, Paez F, et al. Clinical aspects and prognostic factors in elderly patients hos-pitalised for Community-Acquired Pneumonia. Eur J Microbiol Infect Dis 2001; 20: 14–19.
   PubMed Web of Science ®Google Scholar
• Riquelme R, Torres A, El-Ebiary M, et al. Community-acquired pneumonia in the elderly. Etiology, risk, and prog-nostic factors. Am J Respir Crit Care Med 1996; 154: 1450–55.
   PubMed Web of Science ®Google Scholar
• El-Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163, 3: 645–51.
   PubMed Web of Science ®Google Scholar
• Barlett JG, Breiman RF, Mandell LA, File TMJr. Community-acquired pneumonia in adults: guidelines for man-agement. Clin Infect Dis 1998; 26: 811–38.
   PubMed Web of Science ®Google Scholar
• Niederman MS. Community-acquired pneumonia. A North American perspective. Chest 1998; 113: 179s-182s.
   Google Scholar
• Mandell LA, Campbell GDJr. Nosocomial pneumonia guidelines. An international perpective. Chest 1998; 113: 188–93.
   Google Scholar
• Naber KG, Vogel F, Scholz H. The rational use of antibiotics in general practice. Recommendations of an Expert Committee of P. Ehrlich Society for Chemotherapy. MMW 1999; 140: 118–27.
   Google Scholar
• Niederman MS, Brass JB, Campbell GD Jr., et al. Guidelines for the initial empiric therapy of community-acquired pneumonia. Proceedings of an American Thoracic Society Consensus Conference. Am Rev Resp Dis 1993; 148: 1418–26.
   PubMed Web of Science ®Google Scholar
• Bernstein JM. Treatment of community-acquired pneu-monia - IDSA Guidelines. Chest 1999; 115: 9s-13s.
   Google Scholar
• Woodhead M. Community-acquired pneumonia guide-lines. An international comparison. A view from Europe. Chest 1998; 113: 183s-187s.
   Google Scholar
• Fein AM. Pneumonia in the elderly: Overview of diag-nostic and therapeutic approaches. Clin Infect Dis 1999; 28: 726–9.
   PubMed Web of Science ®Google Scholar
• The British Thoracic Society. Guidelines for manage-ment of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346–50.
   Google Scholar
• Inouye SK, Pedruzzi PN, Robinson JT, et al. The importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998; 279: 1187–93.
   PubMed Web of Science ®Google Scholar
• Romanelli G, Cravarezza P and Italian Intramuscular Meropenem Study Group. Intramuscular meropenem in the treatment of bacterial infections of urinary and lower respirato-ry tracts. J Antimicrob Chemother 1995; Suppl. A: 109-19.
   Google Scholar
• Jones RN, Barry AL, Thornsberry C. In-vitro studies of meropenem. J Antimicrob Chemother 1989; 24 (Suppl A): 9-28.
   Google Scholar
• Bartolini A, Colao MG, Orsi A, Nicoletti P, Corti G, Paradisi F. Comparative in vitro activity of meropenem against Italian clinical isolates of Gram-negative and Gram-positive aerobic and Gram-negative anaerobic bacteria. Rev Esp Quimioter 1992; 5 (Suppl. 4), 49-53.
   Google Scholar
• Norrby SR, Faulkner KL, Newall PA. Differentiating meropenem and imipenem/cilastatin. Infect Dis. Clin. Pract. 1997; 6: 291–301.
   Web of Science ®Google Scholar
• Birnbaum J, Kahan FM, Kropp H, MacDonald S. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med 1985; 78 (Suppl. A): 3-21.
   Google Scholar
• Moellering RC, Eliopoulos GM, Sentochnik DE. The carbapenems: new broad spectrum betalactam antibiotucs. J Antimicrob Chemother 1989; Suppl. A: 1-71.
   Google Scholar
• Colardyne F, Faulkner KL on behalf of the Meropenem Serious Infections Study Group. Intravenous meropenem ver-sus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalised patients. J Antimicrob Chemother 1996; 38: 523–37.
   Google Scholar
• Sikka P, Jaafar WM, Bozkanat E, El-Solh AA. A com-parison of severity of illness scoring systems for elderly patients with severe pneumonia. Intensive Care Med 2000; 26: 1803–10.
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumo-nia. N Engl J Med 1997; 336: 243–50.
   PubMed Web of Science ®Google Scholar
• Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966; 45: 493–6.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacte-ria that grow aerobically. Approved standard M7-A2. NCCLS, Villanova, Pennyslvania 1990.
   Google Scholar
• Bartlett JG, Brewer NS, Ryan KJ. Laboratory diagnosis of lower respiratory tract infections. In: Washington JA (Ed.). Cumulative techniques and procedures in clinical microbiology (Cumitech7). American society for microbiology, Washington D.C. 1978: 1-18.
   Google Scholar
• Zar JH. Biostatistical analysis. Englewood Cliff, N J: Prentice-Hall, 1996.
   Google Scholar
• Dixon WJ, Brown MB, Engelman L, et al. BMDP sta-tistical software manual. Berkeley, California, University of California Press, 1990.
   Google Scholar
• Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820–37.
   PubMed Web of Science ®Google Scholar
• Schafer H, Ewing S. Pneumonia in the elderly - what makes the difference? Wien Klin Wochenschr 2000; 112 (13): 566–75.
   PubMed Web of Science ®Google Scholar
• Fine MJ, Medsger AR, Stone RA, et al. The hospital discharge decision for patients with community-acquired pneu-monia. Results from the Pneumonia Patient Outcomes Research Team Cohort Study. Arch Intern Med 1997; 157: 47–56.
   Google Scholar
• Ahkee S, Srinath L, Ramirez J. Community-acquired pneumonia in the elderly: association of mortality with lack of fever and leucocytosis. South Med J 1997; 90: 863–4.
   Web of Science ®Google Scholar
• Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997; 157: 1453–59.
   PubMedGoogle Scholar
• Furrer M, Cottagnoud P, Mahlemann K. Haemophilus influenzae infections among hospitalized adult patients. Infection 2000; 28: 351–4.
   PubMed Web of Science ®Google Scholar
• Nadler HL, Sheikh W. A comparison of the in vitro postantibiotic effect of meropenem and imipenem versus selected Enterobacteriaceae and other pathogens. Diagn Microbiol Infect Dis 1993; 17: 71–3.
   PubMed Web of Science ®Google Scholar
• Muder RR. Pneumonia in residents of long-term care facilities: epidemiology, etiology, management and prevection. Am J Med 1998; 105: 319–30.
   PubMed Web of Science ®Google Scholar
• Marry TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalisation: 5-year prospective study. Rev Infect Dis 1989; 11: 586–99.
   PubMedGoogle Scholar
• Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995; Suppl. 36 A: 1-17.
   Google Scholar
• Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36 (suppl. A): 207-23.
   Google Scholar
• Patel JB, Giles RE. Meropenem: evidence of lack of proconvulsive tendency in mice. J Antimicrob Chemother 1995; 24 (Suppl. A): 307-9.
   Google Scholar
• Freifeld AG, Walsh T, Marshall T et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazime versus imipenem. J Clin Oncol 1995; 13: 165–76.
   Google Scholar
• Mouton CP, Bazaldua OV. Common Infections in older adults. Am Fam Physician 2001; 63: 257–8.
   PubMed Web of Science ®Google Scholar
• Norwegian Study Group. Imipenem/cilastatin as monotherapy in severe infections: Comparison with cefo-taxime in combination with metronidazole and cloxacillin. Scand J Infect Dis 1987; 19: 667–75.
   PubMed Web of Science ®Google Scholar
• Wang C, Calandra GB, Aziz MA, Brown KR. Efficacy and safety of imipenem/cilastatin: a review of world-wide clin-ical experience. Rev Infect Dis 1985; 7 (suppl3): 528s-36s.
   Google Scholar
• McCue J. Antibiotic use in the elderly: issues and nonis-sues. Clin Infect Dis 1999; 28: 750–2.
   PubMed Web of Science ®Google Scholar
• A Guidance Document for the Costing Process, Version 1.0. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment; August 1996.
   Google Scholar
• Ontario Medical Association. 1998 Schedule of Benefits. Toronto: Ontario Medical Association; 1998.
   Google Scholar